HAIKOU CITY, China, Aug. 14, 2020 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the quarter ended June 30, 2020.
Second Quarter Highlights
Ms. Zhilin Li, China Pharma's Chairman and CEO, commented, "The COVID-19 outbreak continued to have a substantial negative impact on our sales of pharmaceutical products. Many people try to avoid going to the hospital for fear of cross-contamination or potential infection. However, the majority of our existing products are prescription drugs. The macro-environment has negatively impacted our drug sales in this period. Fortunately, we completed a one-time foreign trade business this quarter. Due to the continued spread of COVID-19 in the international community, COVID-19 testers have become an urgently needed product in many markets. We have actively leveraged market information as well as our expertise to complete the order in an efficient manner." Ms. Li continued, "along with the lasting efforts to place emphasis on the marketing and sales of our current exiting pharmaceutical products, we continue to explore in the field of comprehensive healthcare. Comprehensive healthcare focuses on people's daily life, aging and disease and pays attention to all kinds of risk factors and misunderstandings affecting health. We aim to leverage our expertise in the PRC for the development, manufacture and commercialization of pharmaceutical and comprehensive healthcare products for the benefit of human health."
Second Quarter Results
Revenue increased by 46.8% to $3.8 million for the three months ended June 30, 2020, as compared to $2.6 million for the three months ended June 30, 2019. This increase was mainly due to a foreign trade of COVID-19 testers we completed in the second quarter of 2020. Because of the market demand for COVID-19 related products, we received an export order for diagnostic test, which we purchased from a third party. This one-time business contributed approximately $1.7 million to our revenue for the three months ended June 30, 2020. This is a milestone of our continuous efforts to explore various niche markets, products and regions based on our experiences and abilities.
For the three months ended June 30, 2020, our cost of revenue was $2.6 million, or 70% of total revenue, comparing to $2.4 million, or 94% of total revenue, for the same period in 2019. The decrease in cost of revenue was mainly due to a foreign trade of COVID-19 testers we completed in the second quarter of 2020.
Gross profit for the three months ended June 30, 2020 was $1.1 million, as compared to $0.2 million during the same period in 2019. Our gross profit margin in the three months ended June 30, 2020 was 30.5% as compared to 6.4% during the same period in 2019. The increase in our gross profit margin was mainly due to a foreign trade of COVID-19 testers we completed in the second quarter of 2020.
Our selling expenses for the three months ended June 30, 2020 and 2019 were $0.7 million and $0.5 million, respectively. Selling expenses accounted for 19.3% of the total revenue in the three months ended June 30, 2020, as compared to 19.7% during the same period in 2019. Because of adjustments in our sales practices, and reform of healthcare policies, we reduced number of personnel and expenses to efficiently support our sales and the collection of accounts receivable.
Our general and administrative expenses were both $0.3 million for the three months ended June 30, 2020 and 2019, respectively. General and administrative expenses accounted for 8.6% and 13.0% of our total revenues in the three months ended June 30, 2020 and 2019, respectively.
Our operating income for the three months ended June 30, 2020 was $0.1 million, compared to an operating loss of $0.8 million during the same period in 2019.
Net income for the three months ended June 30, 2020 was $0.01 million, or $0.00 per basic and diluted common share, as compared to net loss of $0.84 million, or $0.02 per basic and diluted common share for the same period a year ago. The decrease in net loss was mainly the result of a foreign trade of COVID-19 testers we completed in the second quarter of 2020.
Six Months Results
Revenue was both $5.5 million for the six months ended June 30, 2020 and 2019, respectively. The first three months in this year was impacted by COVID-19 outbreak in China, however there was one-time revenue from the selling of COVID-19 testers around $1.7 million, leading the revenue back to prior year performance.
Gross profit for the six months ended June 30, 2020 was $1.3 million, compared to $0.8 million in the same period in 2019. Our gross profit margin in the six months ended June 30, 2020 was 24.3% compared to 14.9% in the same period in 2019. The increase in our gross profit margin was mainly due to a foreign trade of COVID-19 testers we completed in the second quarter of 2020.
Net loss for the six months ended June 30, 2020 was $0.6 million, as compared to net loss of $1.3 million for the six months ended June 30, 2019. The decrease of net loss was mainly due to a foreign trade of COVID-19 testers we completed in the second quarter of 2020.
Financial Condition
As of June 30, 2020, the Company had cash and cash equivalents of $1.8 million compared to $1.1 million as of December 31, 2019.
Our net accounts receivable was both $0.6 million as of June 30, 2020 and December 31, 2019, respectively.
For the six months ended June 30, 2020, cash flow used in operating activities was $0.2 million, as compared to cash flow provided by operating activities of $0.2 million for the same period in 2019.
Conference Call
The Company will hold a conference call at 8:30 am E.T. on August 14, 2020 to discuss the results of the second quarter of 2020. Listeners may access the call by registering via the link below:
http://apac.directeventreg.com/registration/event/7427437
A replay of the call will be accessible through August 22, 2020 by dialing 1-855-452-5696 or 61-281-990-299 for international callers, Conference ID # 7427437.
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products, focusing on conditions with high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnique Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit www.chinapharmaholdings.com. The Company routinely posts important information on its website.
Safe Harbor Statement
Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties may include, but are not limited to: the achievability of financial guidance; success of new product development; unanticipated changes in product demand; increased competition; downturns in the Chinese economy; uncompetitive levels of research and development; and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations, except as required by applicable law or regulation.
- FINANCIAL TABLES FOLLOW -
CHINA PHARMA HOLDINGS, INC. |
||||
CONDENSED CONSOLIDATED BALANCE SHEETS |
||||
(Unaudited) |
||||
June 30, |
December 31, |
|||
2020 |
2019 |
|||
ASSETS |
||||
Current Assets: |
||||
Cash and cash equivalents |
$ 1,813,544 |
$ 1,074,979 |
||
Restricted cash |
222,996 |
109,908 |
||
Banker's acceptances |
11,251 |
45,756 |
||
Trade accounts receivable, less allowance for doubtful |
||||
accounts of $17,342,097 and $17,575,100, respectively |
595,733 |
635,371 |
||
Other receivables, less allowance for doubtful |
||||
accounts of $23,715 and $22,729, respectively |
86,065 |
46,643 |
||
Advances to suppliers |
277,900 |
404 |
||
Inventory |
3,852,972 |
3,588,824 |
||
Prepaid expenses |
397,374 |
77,120 |
||
Total Current Assets |
7,257,835 |
5,579,005 |
||
Property, plant and equipment, net |
15,631,653 |
16,313,827 |
||
Operating lease right of use asset |
90,289 |
136,779 |
||
Intangible assets, net |
185,244 |
205,611 |
||
TOTAL ASSETS |
$ 23,165,021 |
$ 22,235,222 |
||
LIABILITIES AND STOCKHOLDERS' EQUITY |
||||
Current Liabilities: |
||||
Trade accounts payable |
$ 1,025,098 |
$ 1,366,330 |
||
Accrued expenses |
180,719 |
189,880 |
||
Other payables |
3,753,356 |
3,560,332 |
||
Advances from customers |
592,961 |
505,398 |
||
Other payables - related parties |
2,152,161 |
2,071,986 |
||
Operating lease liability, current portion |
93,510 |
91,306 |
||
Current portion of construction loan facility |
2,118,794 |
2,150,168 |
||
Current portion of lines of credit |
1,200,650 |
- |
||
Bankers' acceptance notes payable |
222,996 |
109,908 |
||
Total Current Liabilities |
11,340,245 |
10,045,308 |
||
Non-current Liabilities: |
||||
Construction loan facility |
1,977,541 |
2,150,168 |
||
Lines of credit, net of current portion |
706,264 |
- |
||
Operating lease liability, net of current portion |
- |
48,701 |
||
Deferred tax liability |
742,450 |
753,444 |
||
Total Liabilities |
14,766,500 |
12,997,621 |
||
Commitments and Contingencies (Note 14) |
||||
Stockholders' Equity: |
||||
Preferred stock, $0.001 par value; 5,000,000 shares authorized; |
||||
no shares issued or outstanding |
- |
- |
||
Common stock, $0.001 par value; 95,000,000 shares authorized; |
||||
43,579,557 shares and 43,579,557 shares outstanding, respectively |
43,580 |
43,580 |
||
Additional paid-in capital |
23,590,204 |
23,590,204 |
||
Accumulated deficit |
(26,620,246) |
(25,972,402) |
||
Accumulated other comprehensive income |
11,384,983 |
11,576,219 |
||
Total Stockholders' Equity |
8,398,521 |
9,237,601 |
||
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY |
$ 23,165,021 |
$ 22,235,222 |
||
CHINA PHARMA HOLDINGS, INC. |
||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS |
||||||||
AND COMPREHENSIVE INCOME (LOSS) |
||||||||
(Unaudited) |
||||||||
For the Three Months |
For the Six Months |
|||||||
Ended June 30, |
Ended June 30, |
|||||||
2020 |
2019 |
2020 |
2019 |
|||||
Revenue |
$ 3,770,723 |
$ 2,569,408 |
$ 5,534,678 |
$ 5,498,681 |
||||
Cost of revenue |
2,620,925 |
2,405,860 |
4,190,441 |
4,678,603 |
||||
Gross profit |
1,149,798 |
163,548 |
1,344,237 |
820,078 |
||||
Operating expenses: |
||||||||
Selling expenses |
727,642 |
505,866 |
1,053,737 |
984,557 |
||||
General and administrative expenses |
322,445 |
334,550 |
711,004 |
763,367 |
||||
Research and development expenses |
30,044 |
66,008 |
78,863 |
135,926 |
||||
Bad debt (benefit) expense |
(5,318) |
10,092 |
24,928 |
23,404 |
||||
Total operating expenses |
1,074,813 |
916,516 |
1,868,532 |
1,907,254 |
||||
Income (loss) from operations |
74,985 |
(752,968) |
(524,295) |
(1,087,176) |
||||
Other income (expense): |
||||||||
Interest income |
1,212 |
12,119 |
1,598 |
15,376 |
||||
Interest expense |
(63,144) |
(97,254) |
(125,147) |
(184,034) |
||||
Net other expense |
(61,932) |
(85,135) |
(123,549) |
(168,658) |
||||
Income (loss) before income taxes |
13,053 |
(838,103) |
(647,844) |
(1,255,834) |
||||
Income tax expense |
- |
- |
- |
- |
||||
Net income (loss) |
13,053 |
(838,103) |
(647,844) |
(1,255,834) |
||||
Other comprehensive income - foreign currency |
||||||||
translation adjustment |
5,796 |
(811,164) |
(191,236) |
24,701 |
||||
Comprehensive income (loss) |
$ 18,849 |
$ (1,649,267) |
$ (839,080) |
$ (1,231,133) |
||||
Earnings (loss) per share: |
||||||||
Basic and diluted |
$ 0.00 |
$ (0.02) |
$ (0.01) |
$ (0.03) |
||||
Weighted average shares outstanding |
43,579,557 |
43,579,557 |
43,579,557 |
43,579,557 |
||||
CHINA PHARMA HOLDINGS, INC. |
||||
CONSOLIDATED STATEMENTS OF CASH FLOWS |
||||
(Unaudited) |
||||
For the Six Months |
||||
Ended June 30, |
||||
2020 |
2019 |
|||
Cash Flows from Operating Activities: |
||||
Net loss |
$ (647,844) |
$ (1,255,834) |
||
Depreciation and amortization |
1,305,070 |
1,575,870 |
||
Bad debt expense |
24,928 |
23,404 |
||
Inventory write off |
- |
111,533 |
||
Changes in assets and liabilities: |
||||
Trade accounts and other receivables |
(305,183) |
(284,126) |
||
Advances to suppliers |
(279,380) |
(10,615) |
||
Inventory |
(14,136) |
960,946 |
||
Trade accounts payable |
(323,470) |
223,562 |
||
Accrued taxes payable |
279,748 |
(43,632) |
||
Other payables and accrued expenses |
(79,967) |
(369,547) |
||
Change in bankers' acceptance notes payable |
115,468 |
(781,626) |
||
Advances from customers |
95,579 |
31,548 |
||
Prepaid expenses |
(323,553) |
(31,309) |
||
Net Cash (Used in) Provided by Operating Activities |
(152,740) |
150,174 |
||
Cash Flows from Investing Activities: |
||||
Purchases of property and equipment |
(840,449) |
(73,538) |
||
Net Cash Used in Investing Activities |
(840,449) |
(73,538) |
||
Cash Flows from Financing Activities: |
||||
Proceeds from lines of credit |
1,919,818 |
- |
||
Payments of construction term loan |
(142,209) |
(147,475) |
||
Proceeds (payments) of related party payables |
90,551 |
(231,252) |
||
Net Cash Provided by) Used in Financing Activities |
1,868,160 |
(378,727) |
||
Effect of Exchange Rate Changes on Cash |
(23,318) |
768 |
||
Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash |
851,653 |
(301,323) |
||
Cash, Cash Equivalents and Restricted Cash at Beginning of Period |
1,184,887 |
2,460,527 |
||
Cash, Cash Equivalents and Restricted Cash at End of Period |
$ 2,036,540 |
$ 2,159,204 |
||
Cash and Cash Equivalents |
1,813,544 |
1,655,892 |
||
Restricted cash |
222,996 |
503,312 |
||
Cash, Cash Equivalents and Restricted Cash at End of Period |
$ 2,036,540 |
$ 2,159,204 |
||
Supplemental Cash Flow Information: |
||||
Cash paid for income taxes |
$ - |
$ - |
||
Cash paid for interest |
$ 118,374 |
$ 178,991 |
||
Supplemental Noncash Investing and Financing Activities: |
||||
Issuance of banker's acceptances |
$ - |
$ - |
||
Accounts receivable collected with banker's acceptances |
270,453 |
378,585 |
||
Inventory purchased with banker's acceptances |
304,520 |
399,455 |
||
Right-of-use assets obtained in exchange for operating lease obligations |
- |
233,629 |
||
View original content:http://www.prnewswire.com/news-releases/china-pharma-holdings-inc-reports-second-quarter-2020-financial-results-301112379.html
